MA28111A1 - Derives des - Google Patents

Derives des

Info

Publication number
MA28111A1
MA28111A1 MA28965A MA28965A MA28111A1 MA 28111 A1 MA28111 A1 MA 28111A1 MA 28965 A MA28965 A MA 28965A MA 28965 A MA28965 A MA 28965A MA 28111 A1 MA28111 A1 MA 28111A1
Authority
MA
Morocco
Prior art keywords
mch
anxiety
obesity
diabetes
depression
Prior art date
Application number
MA28965A
Other languages
English (en)
Inventor
Kevin K Barvian
Anthony L Handlon
Donald L Hertzog
Clifton E Hyman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA28111A1 publication Critical patent/MA28111A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Dérivés de 3-(4-aminophényl)-thiénopyrimid-4-one servant d'antagonistes de MCH R1 pour le traitement de l'obésité, du diabète, de la dépression et de l'anxiété La présente invention concerne des arylamines nouvelles qui sont des antagonistes du récepteur 1 de l'hormone concentrant la mélanine (MCH R1), des compositions pharmaceutiques les contenant, des procédés pour leur préparation, et leur utilisation dans des médicaments pour le traitement de l'obésité, du diabète, de la dépression et/ou de l'anxiété. Les composés de la présente invention répondent à la formule:
MA28965A 2003-10-23 2006-04-25 Derives des MA28111A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51380003P 2003-10-23 2003-10-23

Publications (1)

Publication Number Publication Date
MA28111A1 true MA28111A1 (fr) 2006-08-01

Family

ID=34549304

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28965A MA28111A1 (fr) 2003-10-23 2006-04-25 Derives des

Country Status (15)

Country Link
US (1) US20070078125A1 (fr)
EP (1) EP1678184A1 (fr)
JP (1) JP2007509158A (fr)
KR (1) KR20060100412A (fr)
CN (1) CN1871242A (fr)
AU (1) AU2004285913A1 (fr)
BR (1) BRPI0415667A (fr)
CA (1) CA2543122A1 (fr)
CO (1) CO5690599A2 (fr)
IL (1) IL174693A0 (fr)
MA (1) MA28111A1 (fr)
MX (1) MXPA06003997A (fr)
NO (1) NO20061909L (fr)
WO (1) WO2005042541A1 (fr)
ZA (1) ZA200603181B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501217A (ja) * 2005-07-15 2009-01-15 アストラゼネカ アクチボラグ 治療薬
ATE429428T1 (de) 2005-09-30 2009-05-15 Hoffmann La Roche Indanderivate als antagonisten des mch-rezeptors
AR056155A1 (es) * 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US7745447B2 (en) 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
CA2626220A1 (fr) 2005-12-21 2007-06-28 Janssen Pharmaceutica N.V. Nouveaux derives de pyrazinone substituee a utiliser lors de maladies mediees par mch-1
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
WO2007093364A1 (fr) 2006-02-15 2007-08-23 Sanofi-Aventis Nouvelles aryldihydroisoquinolinones à substitution azacyclyle, leur procédé de préparation et leur utilisation comme médicaments
BRPI0707869A2 (pt) 2006-02-15 2011-05-10 Sanofi Aventis ariltienopirimidinonas substituÍdas com azaciclil, processo para a sua preparaÇço e seus usos como medicamentos
KR20080094699A (ko) 2006-02-15 2008-10-23 사노피-아벤티스 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도
WO2007093365A2 (fr) 2006-02-15 2007-08-23 Sanofi-Aventis Nouvelles arylthiénopyrimidinones à substitution aminoalcool, leur procédé de préparation et leur utilisation comme médicaments
EA015127B1 (ru) * 2006-06-08 2011-06-30 Эли Лилли Энд Компани Антагонисты мсн-рецепторов
JP2010501553A (ja) * 2006-08-18 2010-01-21 アストラゼネカ アクチボラグ Ｍｃｈｒ１アンタゴニストとしてのチエノピリミジン−４−オン誘導体およびチエノピリダジン−７−オン誘導体
NZ578096A (en) 2007-01-10 2011-11-25 Albany Molecular Res Inc 5-pyridinone substituted indazoles
US7851622B2 (en) 2007-04-25 2010-12-14 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
CN101861311A (zh) 2007-07-21 2010-10-13 阿尔巴尼分子研究公司 5-吡啶酮取代的吲唑
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
EP2406233B1 (fr) * 2009-03-09 2013-11-13 Bristol-Myers Squibb Company Analogues d'aza-pyridone utiles en tant que antagonistes des récepteurs de l'hormone concentrant la mélanine
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
KR20130013199A (ko) * 2011-07-27 2013-02-06 한미약품 주식회사 신규 피리미딘 유도체 및 이를 활성성분으로 포함하는 약학 조성물
PL2747693T3 (pl) 2011-08-26 2018-09-28 On Light Sciences, Inc. Układ i sposób usuwania tatuaży
EP4076527A4 (fr) * 2020-01-10 2024-05-15 Consynance Therapeutics, Inc. Polythérapies de médicaments et leurs méthodes d'utilisation
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
US20070078125A1 (en) 2007-04-05
JP2007509158A (ja) 2007-04-12
MXPA06003997A (es) 2006-07-05
CO5690599A2 (es) 2006-10-31
AU2004285913A1 (en) 2005-05-12
BRPI0415667A (pt) 2006-12-19
NO20061909L (no) 2006-05-03
IL174693A0 (en) 2006-08-20
KR20060100412A (ko) 2006-09-20
ZA200603181B (en) 2008-01-30
WO2005042541A1 (fr) 2005-05-12
CA2543122A1 (fr) 2005-05-12
EP1678184A1 (fr) 2006-07-12
CN1871242A (zh) 2006-11-29

Similar Documents

Publication Publication Date Title
MA28111A1 (fr) Derives des
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
ATE422887T1 (de) Kondensierte heterozyklische verbindungen
MA29693B1 (fr) Derives de xanthine en tant qu'agonistes hm74a selectifs
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
SE9902987D0 (sv) Novel compounds
TNSN08137A1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
PL1716152T3 (pl) Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych
MA26722A1 (fr) Nouveaux composes et medicaments les contenant
MA30778B1 (fr) Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques
MA30999B1 (fr) Composés.
MA30289B1 (fr) Dérivés d'amines
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
TW200510429A (en) Heterocyclic MCHR1 antagonists
DE60237528D1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
TNSN04194A1 (fr) Derives de tropane servant de modulateurs de ccr5
EP2042490A3 (fr) Dérivés du benzoimidazole comme antagonistes du recepteur Vanilloid
SE9902765D0 (sv) Novel compounds
ATE276246T1 (de) Chemische verbindungen
EP2202222A3 (fr) Dérivés d'indène, leur préparation et leur utilisation en tant que médicaments
MA26541A1 (fr) Nouvelles imidazolines, procede pour les preparer, compositions pharmaceutiques les contenant et leur utilisation dans le traitement de maladies soulagees par un traitement avec un antagoniste des recepteurs des prostaglandines
ATE315563T1 (de) Piperidinylmorpholinylderivate als modulatoren der aktivität des chemokinrezeptors
DE60225195D1 (de) Flavaxat-derivate als muscarin-rezeptor antagonisten
TR200103638T2 (tr) IL-8 Reseptör antagonistleri